The United Kingdom is witnessing a growing surge in interest surrounding copyright substances. Beyond the common use of psilocybin and LSD, researchers and adventurers are increasingly focused on less-charted frontiers, particularly this powerful hallucinogen and the relatively new cannabinoid, cannabigerol. This burgeoning scene encompasses clinic